Article Details

Kindred Biosciences (NASDAQ:KIN) Given "Buy" Rating at Aegis

Retrieved on: 2021-02-18 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Kindred Biosciences (NASDAQ:KIN) Given "Buy" Rating at Aegis. View article details on hiswai:

Excerpt

Acadian Asset Management LLC now owns 284,689 shares of the biopharmaceutical company's stock valued at $1,221,000 after purchasing an ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up